PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

January 8, 2024

https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-an-update-on-commercial-progress-and-rd-pipeline-at-42nd-annual-jp-morgan-healthcare-conference-302028256.html

– Unaudited 2023 total revenue of $946 million, representing 35% year-over-year growth –

– Regulatory filings in the EU and US for sepiapterin in PKU, a potential $1 billion global commercial opportunity, remain on track for 2024 –

Read more at prnewswire.com

Related news for (PTCT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.